MXPA06003345A - Derivados de aminopiridina como inhibidores de la no-sintasa inducible. - Google Patents
Derivados de aminopiridina como inhibidores de la no-sintasa inducible.Info
- Publication number
- MXPA06003345A MXPA06003345A MXPA06003345A MXPA06003345A MXPA06003345A MX PA06003345 A MXPA06003345 A MX PA06003345A MX PA06003345 A MXPA06003345 A MX PA06003345A MX PA06003345 A MXPA06003345 A MX PA06003345A MX PA06003345 A MXPA06003345 A MX PA06003345A
- Authority
- MX
- Mexico
- Prior art keywords
- inductible
- aminopyridine
- derivatives
- synthase inhibitors
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 abstract 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03022040 | 2003-10-01 | ||
| PCT/EP2004/052373 WO2005061496A1 (en) | 2003-10-01 | 2004-09-30 | Aminopyridine-derivatives as inductible no-synthase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06003345A true MXPA06003345A (es) | 2006-06-08 |
Family
ID=34707254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06003345A MXPA06003345A (es) | 2003-10-01 | 2004-09-30 | Derivados de aminopiridina como inhibidores de la no-sintasa inducible. |
Country Status (16)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007507463A (ja) | 2003-10-01 | 2007-03-29 | アルタナ ファルマ アクチエンゲゼルシャフト | 誘導性ＮＯシンターゼ阻害剤としてのイミダゾ［４，５−ｂ］ピリジン誘導体 |
| NZ546437A (en) | 2003-10-01 | 2009-09-25 | Altana Pharma Ag | Imidazopyridine-derivatives as inducible NO-synthase inhibitors |
| ATE399168T1 (de) | 2003-10-01 | 2008-07-15 | Nycomed Gmbh | Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| EP1866306B1 (en) | 2005-03-31 | 2009-06-17 | Nycomed GmbH | Imidazopyridine derivatives useful as inos inhibitors |
| JP2010531358A (ja) * | 2007-06-27 | 2010-09-24 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体 |
| US20100278751A1 (en) * | 2009-04-30 | 2010-11-04 | Washington University | Radiolabeled 2-amino-4-alkyl-6-(haloalkyl)pyridine compounds and their use in diagnostic imaging |
| WO2011150156A2 (en) * | 2010-05-26 | 2011-12-01 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| GB201512635D0 (en) | 2015-07-17 | 2015-08-26 | Ucl Business Plc | Uses of therapeutic compounds |
| CN117215117A (zh) | 2017-05-15 | 2023-12-12 | 索尼公司 | 照明单元和显示设备 |
| US12240815B2 (en) * | 2020-02-24 | 2025-03-04 | Northwestern University | Potent and selective human neuronal nitric oxide synthase inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE418966B (sv) * | 1974-02-18 | 1981-07-06 | Haessle Ab | Analogiforfarande for framstellning av foreningar med magsyrasekretionsinhiberande verkan |
| US4045564A (en) | 1974-02-18 | 1977-08-30 | Ab Hassle | Benzimidazole derivatives useful as gastric acid secretion inhibitors |
| GB8307865D0 (en) * | 1983-03-22 | 1983-04-27 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
| AU650953B2 (en) * | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| SE512835C2 (sv) * | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
| AUPP873799A0 (en) * | 1999-02-17 | 1999-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine compounds |
| BR0308785A (pt) | 2002-03-27 | 2005-01-11 | Altana Pharma Ag | Derivados de alcoxipiridina |
| EP1673371B1 (en) | 2003-10-01 | 2008-08-06 | Nycomed GmbH | Imidazopyridine-derivatives as inducible no-synthase inhibitors |
| JP2007507463A (ja) | 2003-10-01 | 2007-03-29 | アルタナ ファルマ アクチエンゲゼルシャフト | 誘導性ＮＯシンターゼ阻害剤としてのイミダゾ［４，５−ｂ］ピリジン誘導体 |
| NZ546437A (en) | 2003-10-01 | 2009-09-25 | Altana Pharma Ag | Imidazopyridine-derivatives as inducible NO-synthase inhibitors |
| ATE399168T1 (de) | 2003-10-01 | 2008-07-15 | Nycomed Gmbh | Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren |
-
2004
- 2004-09-30 EP EP04820599A patent/EP1670798A1/en not_active Withdrawn
- 2004-09-30 JP JP2006530261A patent/JP2007507464A/ja not_active Withdrawn
- 2004-09-30 CN CNB2004800278079A patent/CN100415746C/zh not_active Expired - Fee Related
- 2004-09-30 AU AU2004303515A patent/AU2004303515A1/en not_active Abandoned
- 2004-09-30 BR BRPI0415034-1A patent/BRPI0415034A/pt not_active IP Right Cessation
- 2004-09-30 NZ NZ546394A patent/NZ546394A/en unknown
- 2004-09-30 US US10/573,204 patent/US7317021B2/en not_active Expired - Fee Related
- 2004-09-30 WO PCT/EP2004/052373 patent/WO2005061496A1/en not_active Ceased
- 2004-09-30 KR KR1020067005860A patent/KR20060092219A/ko not_active Withdrawn
- 2004-09-30 EA EA200600601A patent/EA200600601A1/ru unknown
- 2004-09-30 MX MXPA06003345A patent/MXPA06003345A/es not_active Application Discontinuation
- 2004-09-30 CA CA002540230A patent/CA2540230A1/en not_active Abandoned
- 2004-09-30 RS YUP-2006/0206A patent/RS20060206A/sr unknown
-
2006
- 2006-02-08 ZA ZA200601140A patent/ZA200601140B/en unknown
- 2006-02-09 IL IL173628A patent/IL173628A0/en unknown
- 2006-04-24 NO NO20061789A patent/NO20061789L/no not_active Application Discontinuation
-
2007
- 2007-11-16 US US11/984,364 patent/US7781453B2/en not_active Expired - Fee Related
-
2010
- 2010-07-14 US US12/836,279 patent/US20100280002A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20061789L (no) | 2006-04-24 |
| IL173628A0 (en) | 2006-07-05 |
| US7317021B2 (en) | 2008-01-08 |
| CN1856493A (zh) | 2006-11-01 |
| JP2007507464A (ja) | 2007-03-29 |
| US20080176894A1 (en) | 2008-07-24 |
| WO2005061496A8 (en) | 2006-02-16 |
| RS20060206A (sr) | 2008-08-07 |
| NZ546394A (en) | 2009-08-28 |
| BRPI0415034A (pt) | 2006-12-12 |
| US20070043072A1 (en) | 2007-02-22 |
| CA2540230A1 (en) | 2005-07-07 |
| WO2005061496A1 (en) | 2005-07-07 |
| HK1096968A1 (zh) | 2007-06-15 |
| EP1670798A1 (en) | 2006-06-21 |
| US7781453B2 (en) | 2010-08-24 |
| EA200600601A1 (ru) | 2006-10-27 |
| ZA200601140B (en) | 2007-05-30 |
| CN100415746C (zh) | 2008-09-03 |
| KR20060092219A (ko) | 2006-08-22 |
| AU2004303515A1 (en) | 2005-07-07 |
| US20100280002A1 (en) | 2010-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL372926A1 (en) | Piperidine-pyridazones and phthalazones as pde4 inhibitors | |
| DE60310576D1 (en) | 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer | |
| PL369530A1 (en) | Chemical compounds | |
| IL185275A0 (en) | N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same | |
| WO2005087724A3 (en) | Sulphonylpyrroles as hdac inhibitors | |
| ATE353217T1 (de) | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren | |
| IN2012DN02609A (cg-RX-API-DMAC10.html) | ||
| EA200600607A1 (ru) | Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы | |
| SE0103710D0 (sv) | Compounds | |
| WO2005061496A8 (en) | Aminopyridine-derivatives as inductible no-synthase inhibitors | |
| GB0229081D0 (en) | Multifunctional cationic photoinitiators, their preparation and use | |
| ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
| SI1377574T1 (cg-RX-API-DMAC10.html) | ||
| MXPA06000372A (es) | Compuestos de silicio y su uso. | |
| EA200600608A1 (ru) | Производные имидазопиридина как ингибиторы индуцируемой no-синтазы | |
| EA200600609A1 (ru) | Производные имидазопиридина в качестве ингибиторов индуцируемой no-синтазы | |
| ATE398617T1 (de) | Imidazoä4,5-büpyridinderivate als inhibitoren der induzierbaren no-synthase | |
| GB0322750D0 (en) | Organic compounds | |
| PL377613A1 (pl) | Pochodne imidazo[4,5-B]chinoliny i ich zastosowanie jako inhibitorów syntezy NO | |
| GB0226550D0 (en) | Organic compounds | |
| GB0205327D0 (en) | compounds | |
| PL373989A1 (en) | Novel benzonaphthyridines | |
| WO2005108355A3 (de) | Dihydrobenzothiophene | |
| PL377175A1 (pl) | Azotanowe estry pochodnych kwasu fenyloaminotiofenooctowego |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |